석기태 교수
전문진료분야
간염, 지방간, 간경변, 간암, 치료내시경, 고주파 열치료
전화 예약
033) 240-5000
기본정보
학력
2008.09 ~ 2010.08연세대학교 의학 박사 1993.03 ~ 1999.02연세대학교 원주캠퍼스 의학 학사 2001.03 ~ 2003.02연세대학교 내과 석사 |
경력
現 한림대학교춘천성심병원 소화기내과 과장 現 한림대학교 의과대학 내과학 교수 2014 ~ 2016Post-Doc Research Scholar, Department of Medicine, Columbia University, NY, USA Toranomon hospital (Tokyo) 단기방문교수 2007 ~ 2009연세대학교 원주세브란스기독병원 연구강사 및 임상조교수 2004 ~ 2006이라크 자이툰 병원 내과과장 1999 ~ 2004연세대학교 원주세브란스기독병원 수련의 및 전공의 |
학회활동
임상초음파학회 평생회원 대한 소화기항암학회 정회원 대한 Helicobacter 및 상부위장관 연구학회 평생회원 대한 내과학회 평생회원 대한 소화기내시경학회 평생회원 대한 소화기학회 정회원 대한 간학회 평생회원 |
수상이력
Marquis Who's Who (2018) Liver Week Best Presentation (2017) 세계인명사전 Marquis Who's Who 2016 등재 Liver Week 대한간학회 GSK 학술논문상 (2016) Liver week 우수발표상 (2012) 최우수발표상 (2014) 장연구학회 우수연제상 (2009) 소화기내시경학회 월봉학술상 대상 (2008) 대한 Helicobacter 및 상부위장관 연구학회 우수상 (2008) |
논문
1. Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci. 2021 Jun 13;22(12):6326. doi: 10.3390/ijms22126326.
2. Yoon SJ, Kim SK, Lee NY, Choi YR, Kim HS, Gupta H, Youn GS, Sung H, Shin MJ, Suk KT. Effect of Korean Red Ginseng on metabolic syndrome. J Ginseng Res. 2021 May;45(3):380-389. doi: 10.1016/j.jgr.2020.11.002. Epub 2020 Nov 12.
3. Hong JT, Lee MJ, Yoon SJ, Shin SP, Bang CS, Baik GH, Kim DJ, Youn GS, Shin MJ, Ham YL, Suk KT, Kim BS. Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function. J Ginseng Res. 2021 Mar;45(2):316-324. doi: 10.1016/j.jgr.2020.07.004. Epub 2020 Jul 16.
4. Youn GS, Suk KT. Editorial: microbiome modulation by rifaximin in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2021 Feb;53(4):561-562. doi: 10.1111/apt.16218.
5. Gebru YA, Choi MR, Raja G, Gupta H, Sharma SP, Choi YR, Kim HS, Yoon SJ, Kim DJ, Suk KT. Pathophysiological Roles of Mucosal-Associated Invariant T Cells in the Context of Gut Microbiota-Liver Axis. Microorganisms. 2021 Feb 1;9(2):296. doi: 10.3390/microorganisms9020296.
6. Raja G, Gupta H, Gebru YA, Youn GS, Choi YR, Kim HS, Yoon SJ, Kim DJ, Kim TJ, Suk KT. Recent Advances of Microbiome-Associated Metabolomics Profiling in Liver Disease: Principles, Mechanisms, and Applications. Int J Mol Sci. 2021 Jan 25;22(3):1160. doi: 10.3390/ijms22031160.
7. Choi YR, Kim HS, Yoon SJ, Lee NY, Gupta H, Raja G, Gebru YA, Youn GS, Kim DJ, Ham YL, Suk KT. Nutritional Status and Diet Style Affect Cognitive Function in Alcoholic Liver Disease. Nutrients. 2021 Jan 9;13(1):185. doi: 10.3390/nu13010185.
8. Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci. 2020 Dec 28;22(1):199. doi: 10.3390/ijms22010199.
9. Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, Park TS, Sung H, Kim BY, Suk KT. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol. 2021 Jan;27(1):110-124. doi: 10.3350/cmh.2020.0125. Epub 2020 Dec 3.
10. Lee NY, Joung HC, Kim BK, Kim BY, Park TS, Suk KT. et al. Lactobacillus lactis CKDB001 ameliorate progression of nonalcoholic fatty liver disease through of gut microbiome: addendum. Gut Microbes. 2020 Nov 9;12(1):1829449. doi: 10.1080/19490976.2020.1829449.
11. Kim JH, Kang SH, Lee M, Youn GS, Kim TS, Jun BG, Kim MY, Kim YD, Cheon GJ, Kim DJ, Baik SK, Choi DH, Suk KT. Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers (Basel). 2020 Nov 12;12(11):3347. doi: 10.3390/cancers12113347.
12. Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020 Jan 22:1-18. doi: 10.1080/19490976.2020.1712984.
13. Kim TY, Suk KT, Jang JY, Kim MY. The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients. J Korean Med Sci. 2019 Aug 26;34(33):e223. doi: 10.3346/jkms.2019.34.e223.
14. Gupta H, Youn GS, Han SH, Shin MJ, Yoon SJ, Han DH, Lee NY, Kim DJ, Baik SK, Suk KT. Response-Related Factors of Bone Marrow-Derived Mesenchymal Stem Cells Transplantation in Patients with Alcoholic Cirrhosis. J Clin Med. 2019 Jun 17;8(6).
15. Gupta H, Youn GS, Shin MJ, Suk KT. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019 May 5;7(5)
16. Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204
17. Kim HJ, Kim SY, Shin SP, Yang YJ, Bang CS, Baik GH, Kim DJ, Ham YL, Choi EY, Suk KT. Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation. Korean J Intern Med. 2019 Jan 23
18. Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018 Dec;56(12):855-867.
19. Suk KT, Baik SK Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study. Dig Dis Sci. 2018 Jan;63(1):248-256
20. Hong MG, Suk KT Are probiotics effective in targeting alcoholic liver diseases? Probiotics Antimicrob Proteins. 2019 Jun;11(2):335-347.
21. Park TY, Hong M, Sung H, Kim S, Suk KT. Effect of Korean Red Ginseng in chronic liver disease. J Ginseng Res. 2017 Oct;41(4):450-455
22. Suk KT, Kim EJ, Kim DJ, Kim HS, Bang CS, Park TY, Baik GH, Kim SE, Park JW, Park SH, Lee MS, Kim HS, Jang MK, Park SH, Choi E, Kim CH, Sung H, Park CK. Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma.. J Clin Gastroenterol. 2017 Mar;51(3):285-293. doi: 10.1097/MCG.0000000000000671.
23. Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, Kim HS, Jang JY, Lee CH, Kim BS, Jang YO, Cho MY, Jung ES, Kim YM, Bae SH, Baik SK Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial Hepatology.2016; 64(6):2185
24. Suk KT, Mederacke I, Gwak GY, Cho SW, Adeyemi A, Friedman R, Schwabe RF. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut. 2016; 65(10):1721-32
25. Hotaik Sung, Seung Woo Kim, Meegun Hong, Ki Tae Suk Microbiota-based Treatments in Alcoholic Liver Disease. World J Gastroenterol.2016 22:673-82.
26. Meegun Hong, Yoon Hyeong Lee, Seungwoo Kim, Ki Tae Suk, Chang Seok Bang, Jai Hoon Yoon, Gwang Ho Baik, Dong Joon Kim, Myong Jo Kim. Anti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease. J Ginseng Res. J Ginseng Res. 2016 40(3):203-10
27. Lee Y, Kim C, Suk KT, Choi HC, Bang CS, Yoon JH, Baik GH, Kim DJ, Jang MU, Sohn JH. Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis. Metab Brain Dis. 2016 Apr;31(2):369-76.
2. Yoon SJ, Kim SK, Lee NY, Choi YR, Kim HS, Gupta H, Youn GS, Sung H, Shin MJ, Suk KT. Effect of Korean Red Ginseng on metabolic syndrome. J Ginseng Res. 2021 May;45(3):380-389. doi: 10.1016/j.jgr.2020.11.002. Epub 2020 Nov 12.
3. Hong JT, Lee MJ, Yoon SJ, Shin SP, Bang CS, Baik GH, Kim DJ, Youn GS, Shin MJ, Ham YL, Suk KT, Kim BS. Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function. J Ginseng Res. 2021 Mar;45(2):316-324. doi: 10.1016/j.jgr.2020.07.004. Epub 2020 Jul 16.
4. Youn GS, Suk KT. Editorial: microbiome modulation by rifaximin in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2021 Feb;53(4):561-562. doi: 10.1111/apt.16218.
5. Gebru YA, Choi MR, Raja G, Gupta H, Sharma SP, Choi YR, Kim HS, Yoon SJ, Kim DJ, Suk KT. Pathophysiological Roles of Mucosal-Associated Invariant T Cells in the Context of Gut Microbiota-Liver Axis. Microorganisms. 2021 Feb 1;9(2):296. doi: 10.3390/microorganisms9020296.
6. Raja G, Gupta H, Gebru YA, Youn GS, Choi YR, Kim HS, Yoon SJ, Kim DJ, Kim TJ, Suk KT. Recent Advances of Microbiome-Associated Metabolomics Profiling in Liver Disease: Principles, Mechanisms, and Applications. Int J Mol Sci. 2021 Jan 25;22(3):1160. doi: 10.3390/ijms22031160.
7. Choi YR, Kim HS, Yoon SJ, Lee NY, Gupta H, Raja G, Gebru YA, Youn GS, Kim DJ, Ham YL, Suk KT. Nutritional Status and Diet Style Affect Cognitive Function in Alcoholic Liver Disease. Nutrients. 2021 Jan 9;13(1):185. doi: 10.3390/nu13010185.
8. Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci. 2020 Dec 28;22(1):199. doi: 10.3390/ijms22010199.
9. Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, Park TS, Sung H, Kim BY, Suk KT. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol. 2021 Jan;27(1):110-124. doi: 10.3350/cmh.2020.0125. Epub 2020 Dec 3.
10. Lee NY, Joung HC, Kim BK, Kim BY, Park TS, Suk KT. et al. Lactobacillus lactis CKDB001 ameliorate progression of nonalcoholic fatty liver disease through of gut microbiome: addendum. Gut Microbes. 2020 Nov 9;12(1):1829449. doi: 10.1080/19490976.2020.1829449.
11. Kim JH, Kang SH, Lee M, Youn GS, Kim TS, Jun BG, Kim MY, Kim YD, Cheon GJ, Kim DJ, Baik SK, Choi DH, Suk KT. Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers (Basel). 2020 Nov 12;12(11):3347. doi: 10.3390/cancers12113347.
12. Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020 Jan 22:1-18. doi: 10.1080/19490976.2020.1712984.
13. Kim TY, Suk KT, Jang JY, Kim MY. The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients. J Korean Med Sci. 2019 Aug 26;34(33):e223. doi: 10.3346/jkms.2019.34.e223.
14. Gupta H, Youn GS, Han SH, Shin MJ, Yoon SJ, Han DH, Lee NY, Kim DJ, Baik SK, Suk KT. Response-Related Factors of Bone Marrow-Derived Mesenchymal Stem Cells Transplantation in Patients with Alcoholic Cirrhosis. J Clin Med. 2019 Jun 17;8(6).
15. Gupta H, Youn GS, Shin MJ, Suk KT. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019 May 5;7(5)
16. Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204
17. Kim HJ, Kim SY, Shin SP, Yang YJ, Bang CS, Baik GH, Kim DJ, Ham YL, Choi EY, Suk KT. Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation. Korean J Intern Med. 2019 Jan 23
18. Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018 Dec;56(12):855-867.
19. Suk KT, Baik SK Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study. Dig Dis Sci. 2018 Jan;63(1):248-256
20. Hong MG, Suk KT Are probiotics effective in targeting alcoholic liver diseases? Probiotics Antimicrob Proteins. 2019 Jun;11(2):335-347.
21. Park TY, Hong M, Sung H, Kim S, Suk KT. Effect of Korean Red Ginseng in chronic liver disease. J Ginseng Res. 2017 Oct;41(4):450-455
22. Suk KT, Kim EJ, Kim DJ, Kim HS, Bang CS, Park TY, Baik GH, Kim SE, Park JW, Park SH, Lee MS, Kim HS, Jang MK, Park SH, Choi E, Kim CH, Sung H, Park CK. Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma.. J Clin Gastroenterol. 2017 Mar;51(3):285-293. doi: 10.1097/MCG.0000000000000671.
23. Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, Kim HS, Jang JY, Lee CH, Kim BS, Jang YO, Cho MY, Jung ES, Kim YM, Bae SH, Baik SK Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial Hepatology.2016; 64(6):2185
24. Suk KT, Mederacke I, Gwak GY, Cho SW, Adeyemi A, Friedman R, Schwabe RF. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut. 2016; 65(10):1721-32
25. Hotaik Sung, Seung Woo Kim, Meegun Hong, Ki Tae Suk Microbiota-based Treatments in Alcoholic Liver Disease. World J Gastroenterol.2016 22:673-82.
26. Meegun Hong, Yoon Hyeong Lee, Seungwoo Kim, Ki Tae Suk, Chang Seok Bang, Jai Hoon Yoon, Gwang Ho Baik, Dong Joon Kim, Myong Jo Kim. Anti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease. J Ginseng Res. J Ginseng Res. 2016 40(3):203-10
27. Lee Y, Kim C, Suk KT, Choi HC, Bang CS, Yoon JH, Baik GH, Kim DJ, Jang MU, Sohn JH. Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis. Metab Brain Dis. 2016 Apr;31(2):369-76.